Background: Lymphopenia is associated with disease activity in adult patients with systemic lupus erythematosus (SLE), but no similar studies exist among children. Furthermore, lymphopenia has only been used as a parameter of disease activity in the SLE disease activity index (SLEDAI), but not as an independent marker. Objectives: This study aimed to ascertain lymphopenia as an independent marker related to disease activity in children with SLE. Methods: This was a retrospective cohort study on patients newly diagnosed with SLE. The data were collected from January 2009 to March 2017, including clinical manifestations, complete blood counts, anti-dsDNA, and Mexican-SLEDAI (MEX-SLEDAI) scores. Statistical analysis was performed using the Chi-square test, Student’s t-test, and ROC curve analysis. Results: A total of 103 patients, aged from 12 to 18 years, participated in the study. Of these, 58 patients (56.3%) exhibited lymphopenia. The most commonly observed clinical manifestations in the lymphopenia group included nephritis (72.4%), hypertension (24.1%), and leukopenia (36.2%), with p < 0.05. Furthermore, neuropsychiatric SLE was found exclusively in the lymphopenia group. A negative correlation was observed between lymphocyte counts and anti-dsDNA levels (r = −0.24), as well as between lymphocyte counts and the MEX-SLEDAI score (r = −0.63, with p < 0.05). The receiver operating characteristic (ROC) curve indicated that a lymphocyte count with a cut-off point of ≤1738/mm3 is significant for predicting anti-dsDNA reactivity. Conclusions: Lymphopenia is significantly correlated with higher anti-dsDNA levels and increased disease activity, potentially serving as an independent marker of disease activity in children with SLE. However, further research is needed.
Background: Adequate sleep is essential for neurodevelopment and immune regulation, yet adolescents with childhood-onset systemic lupus erythematosus (cSLE) are at high risk for sleep disturbances. While these associations are well-documented in adults, data on the pediatric population remains limited. This study evaluated sleep quality in Indonesian adolescents with cSLE and examined its association with psychosocial distress. Methods: This cross-sectional study enrolled 60 adolescents (aged 10–18 years) diagnosed with cSLE at a tertiary hospital in Bandung, Indonesia. Psychosocial status was screened using the Pediatric Symptom Checklist-17 (PSC-17), and sleep quality was assessed via the Pittsburgh Sleep Quality Index (PSQI). Disease activity was measured using the MEX-SLEDAI. The data were analyzed using Chi-squared or Fisher’s exact tests as appropriate and Spearman correlations. A p-value less than or equal to 0.05 was deemed significant. Results: The prevalence of poor sleep quality (PSQI ≥ 5) was 41.7%, while 18.3% of participants exhibited psychosocial distress, predominantly in the internalizing domain (16.7%). A significant association was found between psychosocial distress and poor sleep quality ( p = 0.039). Adolescents with psychosocial distress had a 2.10 times higher risk of poor sleep (95% CI: 1.24–3.55). Notably, inpatient status was significantly associated with worse sleep compared to outpatients ( p = 0.030). PSC-17 scores showed a positive correlation with total PSQI scores ( r = 0.301, p = 0.019) and were specifically linked to the daytime dysfunction dimension ( r = 0.365, p = 0.004). Conclusion: Poor sleep quality is common among adolescents with cSLE and is significantly associated with psychosocial distress, particularly reflected in daytime dysfunction. These findings support integrating routine screening of sleep quality and psychosocial distress into comprehensive cSLE care and highlight the need for larger longitudinal studies to clarify causal pathways and identify modifiable drivers of sleep disturbance.
Background: Despite the widespread implementation of Hepatitis B vaccination, some children fail to develop protective immunity. Thus, identifying markers for vaccine unresponsiveness is crucial for optimizing current strategies. As interleukin-12 (IL-12), a central cytokine in Th 1 immune activation, has shown potential as a predictive biomarker, the aim of this study was to determine its role in the Hepatitis B vaccine response, highlighting novel findings regarding the threshold level of IL-12 in the pediatric population in doing so. Methods: A cross-sectional study was conducted on a community in Bandung City. The subjects were 7–12-month-old babies who had completed primary Hepatitis B vaccination (0, 2, 3, and 4 months of age). Blood tests for anti-HB examination were performed with a Chemiluminescent Microparticle Immunoassay (CMIA) to determine the response and non-response groups, and an Enzyme Immunosorbent Assay (ELISA) was used for IL-12 detection. Data were analyzed using the Kruskal–Wallis test, Chi-square test, Spearman Correlation, and Receiver Operating Characteristics. Statistical analysis was conducted with SPSS version 18.0. Results: The results of this study indicate that 4.5% of the subjects were unresponsive to the Hepatitis B vaccine. The most important finding was a significant correlation between IL-12 and the presence of anti-HB titers in the responsive and non-responsive groups (p = 0.016). The Receiver Operating Characteristics (ROC) curve for IL-12 identified a cut-off point of ≥10.65 pg/mL (>100 mIU/mL in anti-HBs), with a sensitivity of 64.23%, specificity of 68.75%, and accuracy of 65.2%. Conclusions: Interleukin-12 can be considered as an early candidate biomarker for responsiveness to the Hepatitis B vaccine in children.